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below. During the period of TH, there was essentially minimal response as 7 out of 8 pts
had 0% of platelet inhibition and 1 patient had marginal response of 7%. Platelet
inhibition became apparent during the re-warming phase but appeared to be relatively
delayed.
Conclusions: In this pilot trial, we found that platelet inhibition with clopidogrel was
minimal during the period of TH. These results raise concerns regarding the potential risks
of stent thrombosis in pts receiving stents and managed with TH.
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Background: Post-treatment platelet reactivity (PR) is associated with ischemic and
bleeding events in patients receiving P2Y12-ADP receptor antagonists.We aimed to the
relationship between post-treatment PR after a 60 mg loading dose of prasugrel and
one-year thrombotic and bleeding events.
Methods: Patients were prospectively included in this observational multicentre study if
they had a successful PCI for an ACS and received prasugrel. VASP index was measured
after prasugrel LD. Endpoint included the rate of thrombotic events (cardiovascular death,
myocardial infarction and stent thrombosis) and bleeding events (TIMI) at one year.
Results: Three hundreds and one patients were enrolled. Nine patients (3%) were lost to
follow-up at one year. The rates of thrombotic and bleeding events at one year were 7.5
and 6.8% respectively. The mean VASP index after a 60mg LD of prasugrel was
3423% and 76 patients (25%) were considered as having high on-treatment platelet
reactivity (HTPR). Patients with HTPR had a higher rate of thrombotic events compared
to good responders (19.7 vs 3.1%;p0.001). Patients with a minor or major non-CABG
related TIMI bleeding had lower PR compared to patients with no bleeding events
(2118 vs 3523%;p0.008). In multivariate analysis, the VASP index predicted both
thrombotic and bleeding events (OR: 1.44 (95% CI: 1.2–1.72; p0.001 and 0.75 (95%
CI: 0.59–0.96;p0.024 (respectively).
Conclusions: Platelet reactivity measurement after prasugrel LD predicts both ischemic
and bleedings events at one year follow-up for ACS patients undergoing PCI.
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Background: Stent thrombosis is a feared complication following stent implantation.
The multi-factorial causes include low anti-platelet response (LR) to the routinely used
drug, clopidogrel. Newer anti-platelet drugs such as prasugrel and ticagrelor have higher
potency with less inter-individual variability in platelet response, however with an
increased bleeding risk. We sought to evaluate the safety and anti-platelet effect of
double-dose clopidogrel as compared with normal-dose prasugrel in patients with
clopidogrel LR undergoing non-urgent PCI.
Methods: TAILOR is a randomized, open-label, single-centre trial. All patients
pre-treated with clopidogrel and undergoing PCI were screened for clopidogrel LR by
whole-blood aggregometry, using the Multiplate analyzer® (Dynabyte, Germany) where
low response to clopidogrel was defined as Multiplate ADP  70 units. Patients
demonstrating LR were randomized to either 150 mg clopidogrel or 10 mg prasugrel (5
mg for patients  75 years or  60 kg).
Results: Of 990 patients screened, 246 (24.9%) exhibited LR to clopidogrel. Of these,
100 (40.5%) were randomized to one of the two regimens (n50 in each group); the
remaining served as controls. Main reasons for non-inclusion were previous stroke,
ongoing anti-coagulant treatment or inability to return for follow up visit. At 1 month,
anti-platelet response was normalized in a total of 67 patients: 37 (75.5%) in the prasugrel
vs 30 (61.2%) in the clopidogrel group (p0.123, unadjusted). Overall, prasugrel resulted
in a greater decrease in Multiplate ADP values (30.121.2 U for prasugrel vs 21.222.4
U for clopidogrel (p0.046)). There were no bleeding episodes, myocardial infarction,
stroke or death during the follow-up.
Conclusions: Tailoring of anti-platelet treatment in patients with clopidogrel LR
undergoing non-urgent PCI translates into improved platelet inhibition with both normal-
dose prasugrel and double-dose clopidogrel, however with a more pronounced effect with
prasugrel.
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Background: Patients with prior coronary artery bypass graft surgery (CABG) who
present with an acute coronary syndrome have high risk for recurrent events. Whether
more intensive antiplatelet therapy with ticagrelor might be beneficial compared to
clopidogrel is unknown. In this substudy of the PLATO trial we studied the effects of
randomized treatment dependent on history of CABG.
Methods: Patients participating in PLATO were classified according to whether they had
prior CABG. The trial’s primary and secondary end points were compared using Cox
proportional hazards regression.
Results: Of the 18,613 study patients, 1,133 (6.5%) had prior CABG, of whom 353
(31%) underwent percutaneous coronary intervention in a saphenous vein graft and 190
(17%) in a native coronary artery. Prior CABG patients had more high risk characteristics
at study entry, experienced more clinical events during follow-up, but had less major
bleeding (Table). The primary endpoint (composite of cardiovascular death, myocardial
infarction, and stroke) was reduced to a similar extent by ticagrelor among patients with
[19.6% vs. 21.4%; hazard ratio (HR), 0.90 (0.69, 1.17)] and without [9.2% vs. 11.0%; HR,
0.84 (0.76, 0.93), Pinteraction0.66] prior CABG. Major bleeding was similar with
ticagrelor vs. clopidogrel among patients with [8.1% vs. 8.7%; HR, 0.93 (0.61, 1.43)] and
without [11.8% vs. 11.4%; HR, 1.04 (0.95, 1.14), Pinteraction0.61] prior CABG.Table:
Outcomes in patients with and without prior coronary artery bypass graft surgery
(CABG).
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Endpoint
Prior
CABG
(N1133)
No prior
CABG
(N17495) HR (95% CI) p
Efficacy
Primary Outcome:
CV Death / MI
(excluding silent) /
Stroke
20.5 (216) 10.1 (1662) 2.06 (1.79, 2.38) .0001
CV
death/MI/stroke in
patients intended
for invasive
management
18.9 (131) 9.3 (1106) 2.03 (1.69, 2.43) .0001
All Cause Death /
MI (excluding
silent) / Stroke
21.4 (225) 10.6 (1741) 2.05 (1.79, 2.36) .0001
Cardiovascular
Death (includes
vascular and
unknown deaths)
7.2 (75) 4.4 (720) 1.61 (1.27, 2.04) .0001
All Cause Death 8.2 (85) 5.0 (820) 1.60 (1.28, 2.00) .0001
Myocardial
Infarction
(excluding silent)
13.8 (144) 5.9 (953) 2.39 (2.01, 2.85) .0001
Any Stent
Thrombosis
(definite, probable
or possible)
3.5 (33) 2.2 (339) 1.48 (1.04, 2.12) 0.0307
Bleeding (study
criteria)
Any major bleeding 8.4 (84) 11.6 (1806) 0.72 (0.58, 0.89) 0.0029
Coronary Procedure
Related Major
Bleeding
5.0 (51) 9.0 (1426) 0.55 (0.42, 0.73) .0001
Non-Coronary
Procedure Related
Major Bleeding
0.2 (2) 0.4 (62) 0.51 (0.12, 2.08) 0.3484
Conclusions: Prior CABG patients represent a high risk cohort for death and recurrent
cardiovascular events but have lower risk for major bleeding. A reduction in ischemic
events without increase in major bleeding occurred with ticagrelor vs. clopidogrel in prior
CABG patients, similar to the results in non-prior CABG patients.
TCT-740
Clinical impact of extended dual antiplatelet therapy after percutaneous
coronary interventions in the drug-eluting stent era: a meta-analysis of
randomized trials
Salvatore Cassese1, Robert Byrne1, Tomohisa Tada1, Lamin King1,
Adnan Kastrati1
1Deutsches Herzzentrum Munich, Munich, Germany
Background: There is still uncertainty regarding the optimal dual antiplatelet therapy
(DAPT) duration after percutaneous coronary interventions (PCI). We evaluate benefits
and risks of extending DAPT after PCI in the drug-eluting stent era.
Methods: We searched electronic databases (Medline, EMBASE, the Cochrane Central
Register of Controlled Trials), relevant websites, reference lists, conference abstracts,
reviews, chapters in books and proceedings of advisory panels for the US Food and Drug
Administration, for randomized controlled trials investigating the clinical impact of
extending DAPT duration in patients undergoing PCI. The primary endpoint was
all-cause death. The secondary endpoints were myocardial infarction (MI), stent throm-
bosis (ST), cerebrovascular accidents (CVA) and Thrombolysis in Myocardial Infarction
(TIMI) major bleeding.
Results: We included four trials which randomized 8,231 patients (50.2%, extended
DAPT duration versus 49.8%, control duration). A total of 8,158 patients (99.1%) were
available for final analyses. Median DAPT duration was 16.8 versus 6.2 months for the
extended DAPT and control groups, respectively. At follow-up (median 16.8 months)
extending DAPT duration did not reduce all-cause death (odds ratio [95% confidence
interval]  1.15 [0.85-1.54], p0.36), MI (0.95 [0.66-1.36], p0.77), ST (0.88 [0.43-
1.81], p0.73) or CVA (1.51 [0.92-2.47], p0.10). Conversely, extended DAPT duration
clearly increased the risk of TIMI major bleeding (2.64 [1.31-5.30], p0.006).
Conclusions: Extending dual antiplatelet therapy duration after percutaneous coronary
interventions increased the risk of bleeding without reducing the incidence of death,
myocardial infarction, stent thrombosis or cerebrovascular accidents.
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Background: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor
significantly reduced the risk of thrombotic events compared to clopidogrel in patients
with acute coronary syndromes (ACS). We aimed to investigate whether clinical
presentation (STEMI vs. NSTE-ACS) has any interaction with platelet inhibition between
ticagrelor and clopidogrel.
Methods: In a non-prespecified, single-center, pharmacodynamic analysis of the PLATO
randomized, blinded, placebo-controlled trial, platelet inhibition was compared in patients
randomized to clopidogrel (n55) or ticagrelor (n53) at 24-48 hours of receiving
loading doses (LD) and during the maintenance period (7 days) of treatment. Maximal
platelet aggregation (MPA) was measured with light transmission aggregometry using ADP
5 M. P values for interaction between STEMI and NSTE-ACS were calculated regarding
mean MPA and for the odds of high platelet reactivity (HPR, defined as MPA46%).
Results: In 77(71.3%) patients with STEMI and 31(28.7%) with NSTE-ACS, 94 loading
phase and 150 maintenance phase measurements were performed. Both after the LD and
MD, patients on ticagrelor showed significantly lower MPA values compared to
clopidogrel without any interaction between STEMI and NSTE-ACS (p for interaction:
0.33 and 0.28 after LD and MD, respectively; Table 1) In line with these findings, patients
randomized to ticagrelor experienced a huge reduction in the odds for HPR regardless of the
clinical presentation (p for interaction: 1.00 and 0.30 after LD and MD, respectively; Table 1).
Mean difference
in MPA
(ticagrelor-
clopidogrel, %) 95% CI P interaction
After loading dose
STEMI 27.67 34.19; 21.15 0.30
NSTE-ACS 32.85 41.05;24.65
During maintenance
dose
STEMI 15.93 22.01; 9.85 0.28
NSTE-ACS 21.91 30.79;13.03
Odds ratio for
HPR (ticagrelor
vs. clopidogrel) 95% CI
P
interaction
After loading dose
STEMI 0.02 0.00; 0.20 1.00
NSTE-ACS 0.02 0.00; 0.54
During maintenance
dose
STEMI 0.12 0.04; 0.39 0.30
NSTE-ACS 0.02 0.00; 0.44
Conclusions: MPA values and the rate of HPR were largely and significantly reduced in
patients randomized to ticagrelor both after LD and MD, regardless of the clinical
presentation. This post-hoc, single-center, pharmacodynamic analysis of the PLATO trial
suggest no attenuation of platelet inhibition in patients presenting with STEMI compared
to those with NSTE-ACS.
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Background: Twelve months duration of dual antiplatelet therapy (DAPT) after
implantation of a drug-eluting stent (DES) is recommended to decrease risk of stent
thrombosis (ST). Controversies surround the optimal duration of DAPT for reducing risk
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